Please check your internet connection and try again.
# L-Ornithine L-Aspartate
## Overview
L-Ornithine L-Aspartate (LOLA) is a combination of two amino acids, L-ornithine and L-aspartate. It is primarily used in the management of hyperammonemia, particularly in patients with liver disease.
## Primary Indications
* Hepatic encephalopathy (HE) secondary to cirrhosis.
* Hyperammonemia.
## Adult Dosing
* **Oral:** Typically 3 to 6 grams by mouth three times daily. The total daily dose can range from 9 to 18 grams.
* **Intravenous:** 5 grams by mouth every 8 hours. A dose of 10 grams intravenously over 30 minutes every 8 hours has also been used.
## Pediatric Dosing
Dosing in pediatric populations is not well-established and should be individualized based on clinical response and tolerance. Some sources suggest doses similar to adult oral regimens may be used in adolescents.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are typically recommended, but caution is advised due to potential for accumulation.
* **Hepatic Impairment:** LOLA is used to *treat* complications of hepatic impairment, not generally dose-adjusted for severity beyond the underlying liver disease.
## Contraindications
* Known hypersensitivity to L-ornithine L-aspartate or its components.
* Severe kidney disease (renal failure).
* Rare metabolic disorders like ornithine transcarbamylase deficiency (though it's primarily used to treat ammonia buildup, underlying specific enzyme deficiencies might warrant extreme caution or avoidance).
## Adverse Effects
Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. Less commonly, allergic reactions can occur.
## Key Drug Interactions
No significant drug interactions are well-documented. However, concurrent use with other ammonia-lowering agents should be monitored for additive effects or toxicity.
## Monitoring
* Serum ammonia levels.
* Hepatic function tests.
* Renal function.
* Mental status and neurological signs for HE.
## Clinical Pearls
* LOLA aims to lower ammonia levels by promoting ammonia detoxification in the liver (urea cycle) and peripheral tissues.
* Oral administration may be preferred for chronic management, while IV is typically used for acute episodes of HE.
* Efficacy can vary, and it is often used as an adjunct to other supportive care measures.
---
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance.*
